Latest news
Sciety invests in a company developing targeted radioimmunotherapy for incurable cancer
Sciety and the network Sciety Venture Partners have invested SEK 68 million in the Swedish radioimmunotherapy company Akiram Therapeutics. The…
Read moreSciety invests in leading health tech company in surgery
PRESS RELEASE. The Sciety syndicate has invested SEK 26 million in Swedish health tech company Encare, whose SaaS solution enables…
Read more
The investment syndicate
Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.
Read more about the Sciety investment syndicate and membership
Services we offer
Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.
What our clients say
“We are very pleased with the outcome of the financing round through Sciety. The whole process was efficient and went very smoothly thanks to Sciety's competent and professional team. It was a fun and constructive collaboration.”
Malte Kühnemund, CEO Cartana
Investment areas
Biotechnology
From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.
Medical technology
From clinical validation phase to expansion phase.
Pharmacology
From late preclinical phase to Phase II clinical trials. All therapeutic areas.
Diagnostics
From clinical validation to expansion phase. All indications.
ICT in healthcare
From pilot phase to expansion phase. Value-enhancing healthcare.
Health tech
From early sales to expansion phase. Preventive health and medical services.
Companies open for investments
We have one or more companies open for investments. Please login or create an account to learn more and invest.
Selection of executed investments
Capitainer AB
Capitainer offers a unique platform for the self-sampling of fingertip blood and plasma based on a patented microfluidic technology. The products enable easy home sampling with high precision, delivering value across the entire care chain.
Akiram Therapeutics
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Pharmnovo AB
PharmNovo develops a novel drug for nerve pain, where there is a high, unmet need for effective and safe treatments. The candidate PN6047 shows effective pain relief in animal models, without the negative side effects associated with existing drugs.